Sign in Subscribe
Pharmaceutical industry

Immunomedics Announces Issuance of Patent for Selective Targeting of Cancer Cells with Radiation or Chemotherapy

Strategic Insights

— 1 min read

Immunomedics, a biopharmaceutical company, has announced the issuance of a patent (U.S. Patent 5,776,095) for a novel method of treating cancer using radiation or chemotherapy. This method involves protecting non-cancerous tissues and cells with targeted drugs that selectively bind to such tissues. The company's chairman, Dr. David M. Goldenberg, explained that the adverse effects of radiation and chemotherapy on normal tissues, such as the bone marrow, limit the dose of treatments that can be given to cancer patients, thus affecting the response rate.

Key Takeaways:

  • Immunomedics has developed a new method of treating cancer using radiation or chemotherapy, which selectively targets cancer cells while protecting non-cancerous tissues and cells.
  • The method involves using targeted drugs that bind selectively to non-cancerous tissues, preventing damage from radiation or chemotherapy.
  • The patent (U.S. Patent 5,776,095) has the potential for the development and commercialization of a next-generation of cancer therapeutics.
  • Immunomedics' Chairman, Dr. David M. Goldenberg, stated that the method has the potential to provide a novel approach to treating cancer, particularly for patients with limited treatment options.
  • The company plans to invite partners to share in the development of this novel therapeutic approach.
  • Immunomedics is focused on developing monoclonal antibodies and antibody fragments for the detection and treatment of cancer and infectious diseases.
  • The company's first product, CEA- Scan(R), has been approved in the United States, Canada, and Europe for the detection of colorectal cancer.
  • Immunomedics has several other diagnostic imaging products and two therapeutic products in clinical trials.

Statistics:

  • The patent (U.S. Patent 5,776,095) describes a novel method of treating cancer with radiation or chemotherapy.
  • The method involves selectively targeting cancer cells while protecting non-cancerous tissues and cells.
  • The company plans to develop and commercialize a next-generation of cancer therapeutics.
  • Immunomedics has several other diagnostic imaging products and two therapeutic products in clinical trials.
  • CEA- Scan(R), the company's first product, has been approved in the United States, Canada, and Europe.

Sources:

  • "Immunomedics Announces Issuance of U.S. Patent for New Cancer Treating Method" (PRNewswire)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • U.S. Patent 5,776,095

Read more